Literature DB >> 21373765

Diagnostic cutoff points for ¹²³I-MIBG myocardial scintigraphy in a Caucasian population with Parkinson's disease.

Africa Muxí1, Pilar Paredes, Ignacio Navales, Francesc Valldeoriola, Carles Gaig, Francisco Lomeña, Andres de la Cerda, Oriol Solà, Beatriz Domenech, Eduardo Tolosa, Francesca Pons.   

Abstract

PURPOSE: Molecular imaging with (123)I-metaiodobenzylguanidine (MIBG) has been used in Parkinson's disease (PD), but there is no consensual index to discriminate between normal and PD patients in the Caucasian population. The purpose of this study was to determine diagnostic cutoff points in the quantification of MIBG cardiac uptake in our population of PD patients. We have also calculated the reproducibility over a range of interpretation expertise.
METHODS: The study included 14 PD patients and 14 normal age- and sex-matched controls. Heart to mediastinum ratios (H/M) were calculated at 15 min (H/M15m) and 4 h (H/M4h) post-injection by three observers with different interpretation expertise, one of whom drew the regions of interest at three different times. The intraobserver and interobserver reliability was calculated (interclass correlation coefficient and coefficient of variability). Diagnosis was estimated by maximizing the Youden index for H/M and washout ratios. Discrimination ability was assessed by the area under the curve (AUC). Sensitivity and specificity were reported, using our thresholds.
RESULTS: The parameter with the best diagnostic accuracy was the H/M4h ratio, with a major AUC (0.976 area under the receiver-operating characteristic curve). The threshold was 1.43 with a 95% confidence interval of 1.37-1.50. Using this threshold, the sensitivity and specificity were 93 and 100%. The interobserver and intraobserver variabilities measuring this ratio were 3.2 and 3.1%, respectively.
CONCLUSION: The diagnostic cutoff point for (123)I-MIBG myocardial scintigraphy in a Caucasian population with PD was 1.43 for the H/M4h index, with a good sensitivity and specificity. The technique is easy to use, with a good reproducibility over a range of interpretation expertise.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21373765     DOI: 10.1007/s00259-011-1754-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  33 in total

1.  Interaction of metaiodobenzylguanidine with cardioactive drugs: an in vitro study.

Authors:  F Huguet; D Fagret; M Caillet; A Piriou; J C Besnard; D Guilloteau
Journal:  Eur J Nucl Med       Date:  1996-05

2.  Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy.

Authors:  P Merlet; C Benvenuti; D Moyse; F Pouillart; J L Dubois-Randé; A M Duval; D Loisance; A Castaigne; A Syrota
Journal:  J Nucl Med       Date:  1999-06       Impact factor: 10.057

3.  Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis.

Authors:  A Cohen-Solal; Y Esanu; D Logeart; F Pessione; C Dubois; G Dreyfus; R Gourgon; P Merlet
Journal:  J Am Coll Cardiol       Date:  1999-03       Impact factor: 24.094

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

6.  Myocardial iodine-labeled metaiodobenzylguanidine 123 uptake relates to age.

Authors:  M Estorch; I Carrió; L Berná; J López-Pousa; G Torres
Journal:  J Nucl Cardiol       Date:  1995 Mar-Apr       Impact factor: 5.952

7.  Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.

Authors:  Kenji Ishibashi; Yuko Saito; Shigeo Murayama; Kazutomi Kanemaru; Keiichi Oda; Kiichi Ishiwata; Hidehiro Mizusawa; Kenji Ishii
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

Review 8.  A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG).

Authors:  K K Solanki; J Bomanji; J Moyes; S J Mather; P J Trainer; K E Britton
Journal:  Nucl Med Commun       Date:  1992-07       Impact factor: 1.690

9.  123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials.

Authors:  Arnold F Jacobson; John Lombard; Gopa Banerjee; Paolo G Camici
Journal:  J Nucl Cardiol       Date:  2009-01-20       Impact factor: 5.952

10.  [Diagnostic value of cardiac 123I-metaiodobenzylguanidine (123I-MIBG) scintigraphy in Lewy body disorders].

Authors:  F Escamilla-Sevilla; M J Pérez-Navarro; M Muñoz-Pasadas; T Ortega-Léon; M Gallego-Peinado; D Cabello-García; M Gómez Río; A Ortega-Moreno; C Carnero-Pardo; A C Rebollo-Aguirre; A Mínguez-Castellanos
Journal:  Neurologia       Date:  2009-04       Impact factor: 3.109

View more
  5 in total

1.  Assessment of global cardiac I-123 MIBG uptake and washout using volumetric quantification of SPECT acquisitions.

Authors:  Berlinda J van der Veen; Imad Al Younis; Albert de Roos; Marcel P M Stokkel
Journal:  J Nucl Cardiol       Date:  2012-06-06       Impact factor: 5.952

2.  Potential diagnostic value of regional myocardial adrenergic imaging using (123)I-MIBG SPECT to identify patients with Lewy body diseases.

Authors:  Adrien Lebasnier; Guillaume Lamotte; Alain Manrique; Damien Peyronnet; Gerard Bouvard; Gilles Defer; Denis Agostini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-28       Impact factor: 9.236

Review 3.  MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis.

Authors:  Giorgio Treglia; Ernesto Cason; Antonella Stefanelli; Fabrizio Cocciolillo; Daniela Di Giuda; Giorgio Fagioli; Alessandro Giordano
Journal:  Clin Auton Res       Date:  2011-07-27       Impact factor: 4.435

4.  Sensitivity and specificity of cardiac metaiodobenzylguanidine scintigraphy in the early diagnosis of Parkinson's disease.

Authors:  Sebastian J Brandl; Stefan Braune
Journal:  Clin Auton Res       Date:  2018-06-05       Impact factor: 4.435

5.  Accuracy and cutoff values of delayed heart to mediastinum ratio with (123)I-metaiodobenzylguanidine cardiac scintigraphy for Lewy body disease diagnoses.

Authors:  Guillaume Lamotte; Rémy Morello; Adrien Lebasnier; Denis Agostini; Gilles L Defer
Journal:  BMC Neurol       Date:  2015-05-15       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.